Methylphenidate warnings updated

Prescribing information for methylphenidate is being updated following a review of the drug's safety conducted by the EMEA earlier this year.

The agency concluded that the benefits of medicines containing methylphenidate outweigh their risks when used to treat ADHD in children aged six years and above.

However, prescribing advice for these products has been updated to emphasise the need to screen and monitor for cardiovascular and psychiatric problems before and during treatment.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more